Advanced search
Publication Cover
Cancer Biology & Therapy Volume 21, 2020 - Issue 9
Submit an article Journal homepage
948
Views
0
CrossRef citations to date
0
Altmetric
Report

Third-line sunitinib treatment in a VHL-mutated metastatic intrahepatic cholangiocarcinoma: a case report and literature review

Xiaofen Lia Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, P.R. ChinaORCID Iconhttps://orcid.org/0000-0002-1064-768X
ORCID Icon,
Limin Gaob Department of Pathology, West China Hospital, Sichuan University, Chengdu, P.R. China
,
Li Zhangc Department of Oncology, Pengzhou People’s Hospital, Pengzhou, P.R. China
,
Hongna Suna Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, P.R. China
&
Hongfeng Goua Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, P.R. ChinaCorrespondence[email protected]
Pages 785-789 | Received 25 Sep 2019, Accepted 09 May 2020, Published online: 18 Jun 2020

  • Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma – evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95–111. doi:10.1038/nrclinonc.2017.157.
  • Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–1229. doi:10.1053/j.gastro.2013.10.013.
  • Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ, Youssef BAM, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234(4):507–517. doi:10.1097/00000658-200110000-00010.
  • Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, et al. 2010. ABC-0 trial investigators cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 362(14):1273–1281.
  • Fouassier L, Marzioni M, Afonso MB, Dooley S, Gaston K, Giannelli G, Rodrigues CMP, Lozano E, Mancarella S, Segatto O, et al. Signalling networks in cholangiocarcinoma: molecular pathogenesis, targeted therapies and drug resistance. Liver Int. 2019;39(Suppl 1):43–62. doi:10.1111/liv.14102.
  • Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, Hama N, Hosoda F, Urushidate T, Ohashi S, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010. doi:10.1038/ng.3375.
  • Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026.
  • Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, Tannir NM, Gombos DS, Fuller GN, Matin SF. Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease. Ann Oncol. 2011;22(12):2661–2666. doi:10.1093/annonc/mdr011.
  • Roma A, Maruzzo M, Basso U, Brunello A, Zamarchi R, Bezzon E, Pomerri F, Zovato S, Opocher G, Zagonel V. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease: clinical outcome
and patterns of radiological response. Fam Cancer. 2015;14(2):309–316. doi:10.1007/s10689-014-9771-y.
  • Dowsiriroj P, Paholpak P, Sirichativapee W, Wisanuyotin T, Laupattarakasem P, Sukhonthamarn K, Kosuwon W, Jeeravipoolvarn P. Cholangiocarcinoma with spinal metastasis: single center survival analysis. J Clin Neurosci. 2017;38:43–48. doi:10.1016/j.jocn.2016.12.048.
  • Sangsin A, Saiudom D, Pongmanee S, Saengsin J, Leerapun T, Natural History MH. Prognostic factors of cholangiocarcinoma with spinal metastasis: a 10-year single center study. Clin Spine Surg. 2018;31(3):E160–E165. doi:10.1097/BSD.0000000000000625.
  • Saeed A, Park R, Al-Jumayli M, Al-Rajabi R, Biologics SW. Immunotherapy, and future directions in the treatment of advanced cholangiocarcinoma. Clin Colorectal Cancer. 2019;18(2):81–90. doi:10.1016/j.clcc.2019.02.005.
  • Loaiza-Bonilla A, Clayton E, Furth E, O’Hara M, Morrissette J. Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine. Ecancermedicalscience. 2014;8:479. doi:10.3332/ecancer.2014.479.
  • Lavingia V, Fakih M. Impressive response to dual and mek inhibition in patients with braf mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review. J Gastrointest Oncol. 2016;7(6):E98–E102.
  • Bian JL, Wang MM, Tong EJ, Sun J, Li M, Miao ZB, Li YL, Zhu BH, Xu JJ. Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation. World J Gastroenterol. 2017;23(23):4311–4316. doi:10.3748/wjg.v23.i23.4311.
  • Javle MM, Shroff RT, Zhu A, Sadeghi S, Choo S, Borad MJ, Lowery MA, El-Khoueiry A, Macarulla T, Philip AP. A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. J Clin Oncol. 2016;34(4_suppl):335. doi:10.1200/jco.2016.34.4_suppl.335.
  • Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–282.
  • Bahleda R, Italiano A, Hierro C, Mita AC, Cervantes A, Chan N, Awad MM, Calvo E, Moreno VGovindan R, et al. Multicenter phase i study of erdafitinib (jnj-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin Cancer Res. 2019;25(16):4888–4897.
  • Mazzaferro V, El-Rayes BF, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh FS, Zagonel V. ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations. J Clin Oncol. 2017;35(15_suppl):4017.
  • Hollebecque A, Borad M, Sahai V, Catenacci DVT, Murphy A, Vaccaro G, Paulson A, Oh D-Y, Feliz L, Lihou C. A Murphy, interim results of fight-202, a phase II, open-label, multicenter study of (Pemigatinib) INCB054828 in patients with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations. Ann Oncol. 2018;29(8):258.
  • Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 Mar 20.
  • Javle M, Kelley RK, Roychowdhury S, KH W, GK A-A, Macarulla T, Sadeghi S, Waldschmidt D, AX Z, Goyal L, et al. Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Ann Oncol. 2018;29(Suppl 8):viii720. doi:10.1093/annonc/mdy424.030.
  • Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. New Engl J Med. 2015;373(8):726–736. doi:10.1056/NEJMoa1502309.
  • Lowery MA, Abou-Alfa GK, Burris HA, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L. Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts. J Clin Oncol. 2017;35(15_suppl):4015.
  • Valle JW, Bousmans N, Zhang W, Walgren RA, Vogel A. Cisplatin and gemcitabine plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase 2 trial. Ann Oncol. 2016;27(suppl_6):712TiP. doi:10.1093/annonc/mdw371.104.
  • Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH. von Hippel-Lindau disease. Lancet. 2003;361(9374):2059–2067. doi:10.1016/S0140-6736(03)13643-4.
  • Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet. 1994;7(1):85–90. doi:10.1038/ng0594-85.
  • Lee JY, Dong SM, Park WS, Yoo NJ, Kim CS, Jang JJ, Chi JG, Zbar B, Lubensky IA, Linehan WM, et al. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res. 1998;58(3):504–508.
  • Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25(7):884–896. doi:10.1200/JCO.2006.06.3602.
  • Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. 2009;94(2):386–391. doi:10.1210/jc.2008-1972.
  • Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res. 2009;15(24):7582–7592. doi:10.1158/1078-0432.CCR-09-2131.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.